These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 10197963

  • 1. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT, Christiaans JA, Kotisaari S, Laitinen JT, Männistö PT, Tuomisto L, Gynther J.
    J Med Chem; 1999 Apr 08; 42(7):1193-202. PubMed ID: 10197963
    [Abstract] [Full Text] [Related]

  • 2. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
    Stark H, Purand K, Hüls A, Ligneau X, Garbarg M, Schwartz JC, Schunack W.
    J Med Chem; 1996 Mar 15; 39(6):1220-6. PubMed ID: 8632428
    [Abstract] [Full Text] [Related]

  • 3. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Handley MK, Yates SL.
    J Pharmacol Exp Ther; 1999 May 15; 289(2):1160-8. PubMed ID: 10215700
    [Abstract] [Full Text] [Related]

  • 4. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Tedford CE.
    J Pharmacol Exp Ther; 1999 May 15; 289(2):1151-9. PubMed ID: 10215699
    [Abstract] [Full Text] [Related]

  • 5. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G, Krause M, Hüls A, Ligneau X, Pertz HH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H.
    J Med Chem; 2004 May 06; 47(10):2678-87. PubMed ID: 15115409
    [Abstract] [Full Text] [Related]

  • 6. [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors.
    Ligneau X, Garbarg M, Vizuete ML, Diaz J, Purand K, Stark H, Schunack W, Schwartz JC.
    J Pharmacol Exp Ther; 1994 Oct 06; 271(1):452-9. PubMed ID: 7965746
    [Abstract] [Full Text] [Related]

  • 7. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M, Kazuta Y, Hayashi H, Yamada S, Matsuda A, Shuto S.
    J Med Chem; 2006 Sep 07; 49(18):5587-96. PubMed ID: 16942032
    [Abstract] [Full Text] [Related]

  • 8. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A, Kiec-Kononowicz K, Stark H, Motyl M, Reidemeister S, Ganellin CR, Ligneau X, Schwartz JC, Schunack W.
    J Med Chem; 1999 Feb 25; 42(4):593-600. PubMed ID: 10052966
    [Abstract] [Full Text] [Related]

  • 9. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H, Hüls A, Ligneau X, Arrang JM, Schwartz JC, Schunack W.
    Pharmazie; 1997 Jul 25; 52(7):495-500. PubMed ID: 9266588
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y, Hirano K, Natsume K, Yamada S, Kimura R, Matsumoto S, Furuichi K, Matsuda A, Shuto S.
    J Med Chem; 2003 May 08; 46(10):1980-8. PubMed ID: 12723960
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
    Ali SM, Tedford CE, Gregory R, Handley MK, Yates SL, Hirth WW, Phillips JG.
    J Med Chem; 1999 Mar 11; 42(5):903-9. PubMed ID: 10072687
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
    De Esch IJ, Vollinga RC, Goubitz K, Schenk H, Appelberg U, Hacksell U, Lemstra S, Zuiderveld OP, Hoffmann M, Leurs R, Menge WM, Timmerman H.
    J Med Chem; 1999 Apr 08; 42(7):1115-22. PubMed ID: 10197956
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
    Ganellin CR, Fkyerat A, Bang-Andersen B, Athmani S, Tertiuk W, Garbarg M, Ligneau X, Schwartz JC.
    J Med Chem; 1996 Sep 13; 39(19):3806-13. PubMed ID: 8809168
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
    Hashimoto T, Harusawa S, Araki L, Zuiderveld OP, Smit MJ, Imazu T, Takashima S, Yamamoto Y, Sakamoto Y, Kurihara T, Leurs R, Bakker RA, Yamatodani A.
    J Med Chem; 2003 Jul 03; 46(14):3162-5. PubMed ID: 12825954
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.